Diligence memo · auto-generated · as of July 2, 2026
EIP Pharma, Inc.
EIP Pharma, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
EIP Pharma, Inc. operates in Pharma, based in BOSTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
EIP Pharma, Inc. has raised $44M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2018-04-02.
Most recent recorded round closed around 2023-07-10.
Valuation (modeled)modeled
Provath models EIP Pharma, Inc. at approximately $8.3M (range $1.7M–$18M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.04× the median modeled value of Series B Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 3.0 yr ago; this sector typically re-raises about every 16 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 7.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 84% of Pharma peers (310 compared).
Modeled value ranks above 33% of those peers.
Closest niche peers: Switch Therapeutics Inc., March Therapeutics, Inc., Affect Therapeutics, Inc., SPR Therapeutics, Inc., Multiply Labs, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.